SUBSCRIBE
SUBSCRIBE
News   Drug Development

Vitae Pharmaceuticals, Inc. Initiates Phase 1 Trial of Novel Renin Inhibitor

September 21, 2009 | 
1 min read
FORT WASHINGTON, Pa.--(BUSINESS WIRE)--Vitae Pharmaceuticals, Inc., an integrated discovery and development company, today announced that it has initiated a Phase 1 clinical trial of its novel cardiovascular agent, VTP-27999.
Clinical research Phase I
MORE ON THIS TOPIC
ASD autism neurodevelopmental spectrum disorder, deficits in social communication and interaction, brain with impairment, hypersensitivity and abnormalities
Neuroscience
Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising
May 27, 2025
 · 
1 min read
 · 
Annalee Armstrong
Red round circle with a pause button or icon against yellow background.
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
May 27, 2025
 · 
2 min read
 · 
Tristan Manalac
Syndeio CEO Derek Small,
Funding
Karuna, Naurex Alumni Launch New Biotech to Modulate Synaptic Plasticity for Neuro Diseases
May 27, 2025
 · 
3 min read
 · 
Heather McKenzie
Business and financial crisis vector concept with businessman falling down the hole. Symbol of market crash, recession, risk, bankruptcy and loss. Eps10 illustration.
Rare diseases
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
May 27, 2025
 · 
2 min read
 · 
Tristan Manalac